Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CAR in R/R FL: is real-world efficacy meeting expectations?

Blood advances·2026

Same author

Marginal Zone Lymphoma With T-Follicular Helper Hyperplasia: Paving the Way for New Concepts in Cellular Plasticity and Unveiling Histopathologic Pitfalls.

The American journal of surgical pathology·2026

Same author

Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression.

Nature communications·2026

Same author

Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphoma.

Leukemia & lymphoma·2026

Same author

Nodal T-follicular helper cell lymphoma with clonal B-cell component: a distinct mutational profile and aggressive clinical behavior.

Leukemia & lymphoma·2026

Same author

Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis.

HemaSphere·2025

Search research articles

Related Experiment Video

Updated: Apr 29, 2026

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

Time has come for immunotherapy in PTCL.

Emmanuel Bachy¹, Bertrand Coiffier¹

¹UNIVERSITY LYON 1.

|May 17, 2014

Summary

This summary is machine-generated.

Brentuximab vedotin shows promise for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This phase 2 study indicates encouraging efficacy for this antibody-drug conjugate (ADC) in a challenging patient population.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Related Experiment Videos

Last Updated: Apr 29, 2026

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Area of Science:

Hematology
Oncology
Clinical Trials

Background:

Peripheral T-cell lymphoma (PTCL) is a group of aggressive non-Hodgkin lymphomas with limited effective treatment options.
Relapsed or refractory PTCL poses a significant therapeutic challenge, often associated with poor prognoses.

Purpose of the Study:

To assess the efficacy and safety of brentuximab vedotin (BV) in patients with relapsed/refractory PTCL.
To evaluate the potential of antibody-drug conjugates (ADCs) as a treatment strategy for PTCL.

Main Methods:

Phase 2 clinical trial design.
Administration of brentuximab vedotin (BV) to patients with relapsed/refractory PTCL.
Evaluation of objective response rate (ORR) and safety profile.

Main Results:

Encouraging efficacy signals observed with brentuximab vedotin (BV).
Positive response rates in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).
Tolerability and safety profile of the antibody-drug conjugate (ADC) were evaluated.

Conclusions:

Brentuximab vedotin (BV) demonstrates encouraging efficacy in the treatment of relapsed/refractory peripheral T-cell lymphoma (PTCL).
BV represents a potential therapeutic option for patients with limited treatment alternatives.
Further investigation in larger trials may be warranted.